Tumor: Oral Squamous Cell Carcinoma
For more information visit www.vetmed.auburn.edu
Purpose of the study: Examine the efficacy of toceranib phosphate (Palladia) as a primary and/or adjuvant agent in the treatment of feline oral squamous cell carcinoma. Palladia is a tyrosine kinase inhibitor that affects the development of blood vessels by targeting receptor tyrosine kinases within tumors. By blocking the signaling of these pathways tumor growth can be slowed. The presence of these receptors (VEGF and VEGFRs) has been well documented in human oral squamous cell carcinomas. This has not been evaluated yet in feline tumors. Evidence continues to accumulate indicating that Palladia can also increase the sensitivity of tumor cells to radiation therapy and that Palladia has some primary activity in feline oral squamous cell carcinomas. Because of these effects, clinical investigation of Palladia as therapy for feline oral squamous cell carcinoma alone or in combination with radiation therapy is indicated.